Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Response to treatment

Time frame · 4 months (data collection duration)

Evaluated as responsive disease (i.e., complete response, partial response), stable disease or progressive disease at the last tumor assessment while on treatment with lanreotide (based on tumor imaging, symptoms, biomarker(s) and/or clinical judgement)

Progression-free survival, after treatment with octreotide

Time frame · 4 months (data collection duration)

For evaluating progression-free survival events will include radiographic progression per investigator, biomarker progression per investigator, symptom progression per investigator, and death. Adverse events (AEs) will not be considered as an event.

Duration of response to lanreotide, after treatment with octreotide

Time frame · 4 months (data collection duration)

For evaluating duration of response events will include radiographic progression per investigator, biomarker progression per investigator, symptom progression per investigator, AEs, and death. Open ended responses will be reviewed during the analysis and determined to be an eligible "event" or not at that time.

Duration of treatment with octreotide and duration of treatment with lanreotide

Time frame · 4 months (data collection duration)

Duration of octreotide treatment assessed as time from start of octreotide treatment to stop of octreotide treatment. Duration of lanreotide treatment assessed as time from lanreotide initiation to end of lanreotide treatment (censored at the date of last administration (+lanreotide frequency) for patients who had ongoing lanreotide treatment).

Severity of Adverse Events

Time frame · 4 months (data collection duration)

Summarized separately during treatment with octreotide and during treatment with lanreotide, as available

Reasons for switching from octreotide to lanreotide

Time frame · 4 months (data collection duration)

Summarized descriptively

Levels of 5-hydroxyindoleacetic acid (5-HIAA) (urine test or blood test) before treatment with octreotide, during treatment with octreotide and during treatment with lanreotide, as available

Time frame · 4 months (data collection duration)

Summarized descriptively

Levels of Chromogranin A (CgA) before treatment with octreotide, during treatment with octreotide and during treatment with lanreotide, as available

Time frame · 4 months (data collection duration)

Summarized descriptively

Severity of symptoms (i.e., flushing, diarrhea, dyspnea, abdominal pain, edema, nausea) before treatment with octreotide, during treatment with octreotide, and during treatment with lanreotide, as available

Time frame · 4 months (data collection duration)

Proportion of patients reporting each symptom